HMHirofumi Miyake

Hirofumi Miyake

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hirofumi Miyake has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre MYKO study

    by Mahiro Yamamoto, Shogo Matsuda, Katsumasa Oe, Chifumi Akiyama, Takayasu Suzuka, Ran Nakashima, Hideaki Tsuji, Tsuneo Sasai, Yasuhiro Nohda, Tsuneyasu Yoshida, et al.

    Objectives: To identify baseline predictors and develop a clinical risk stratification model for severe infections (SIs) in patients with idiopathic inflammatory myopathy (IIM) after remission induction therapy. Methods: We enrolled patients diagnosed with IIM between 1991 and 2024 from three Japanese centres participating in the multicentre Idiopathic Inflammatory Myopathy and Anti-synthetase Syndrome (MYKO) cohort. SI was defined as an infection requiring i.v. antibiotics or hospitalization. We explored the risk factors for predicting SI in patients with IIM by comparing the initial demographic, clinical, laboratory and treatments between the SI and non-SI groups. Results: Among 349 patients with IIM, 14.6% of patients developed SIs after remission induction therapy over a median follow-up of 4.7 years. Patients who developed SI exhibited significantly lower baseline albumin levels, and significantly higher baseline CRP, lactate dehydrogenase and surfactant protein (SP-D) levels than those without SI. Multivariate logistic regression analysis demonstrated that elevated CRP and SP-D levels were independently associated with SI. Serum CRP levels remained significantly higher in the SI group than in the non-SI group over the 2-year period after immunosuppressive therapy, and the serum SP-D levels tended to be higher in the SI group. The 10-year SI rate was significantly different among patients with IIM stratified by the number of risk factors, defined as CRP ≥ 0.8 mg/dl and SP-D ≥ 96.2 ng/ml. Conclusions: This model, which consists of CRP ≥ 0.8 mg/dl, SP-D ≥ 96.2 ng/ml, is useful for clinical risk stratification of SI after remission induction therapy in IIM.

  • Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling

    by Tsuneyasu Yoshida, Ryosuke Hiwa, Mikihito Shoji, Atsushi Manabe, Keiichiro Kadoba, Tomoki Taniguchi, Ryosuke Tsuge, Shogo Matsuda, Takuya Kotani, Ayana Okazaki, et al.

    Objectives: To evaluate the association between avacopan (AVA) use and recurrent relapse and severe infection in patients with ANCA-associated vasculitis, with particular attention to time-varying treatment and glucocorticoid (GC) exposure. Methods: In this multicentre retrospective cohort study, AVA use was modelled as a time-varying exposure. Stabilized inverse probability of treatment weighting was used to adjust for baseline differences. Recurrent relapse and severe infection, defined as an infection requiring hospitalization, were analysed using time-dependent Cox proportional hazards models based on the Andersen–Gill formulation. Exploratory models additionally incorporated time-varying and cumulative prednisolone exposure. Results: A total of 387 patients were included, of whom 52 received AVA and 335 did not. AVA exposure was associated with a lower estimated risk of severe infection (adjusted HR 0.22, 95% CI 0.07–0.68; P = 0.008), whereas no statistically significant difference in recurrent relapse risk was observed. AVA use was also associated with lower prednisolone exposure over time. This association with severe infection remained directionally consistent in GC-adjusted models, although its magnitude varied depending on model specification. Conclusion: In this multicentre real-world cohort, AVA exposure was associated with a lower estimated risk of severe infection and reduced GC exposure, whereas no statistically significant reduction in recurrent relapse risk was observed. These findings suggest that an AVA-containing treatment strategy may be associated with improved infection-related outcomes in routine practice, although the observational design precludes causal inference.

  • Open Access

    Functional Hyperthermia Presenting as Fever of Unknown Origin With Normal Inflammatory Markers in an Adolescent

    by Ryuichi Minoda Sada, Hirofumi Miyake, Hiroyuki Akebo, Kazuhiro Hatta

  • Clinical outcomes after switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis: A single-centre retrospective cohort study

    by Daichi Umemoto, Eri Iwai-Kanai, Kazuhiro Hatta, Hirofumi Miyake

    Objectives: To investigate the impact of switching to benralizumab on flare risk in patients with eosinophilic granulomatosis with polyangiitis (EGPA) previously treated with mepolizumab. Methods: We conducted a single-centre retrospective cohort study including 26 patients with EGPA who received mepolizumab. A landmark analysis was performed at 910 days after mepolizumab initiation (median time to switching), and patients were grouped according to treatment. The primary outcome was disease flares requiring treatment intensification. We used a Cox model with treatment switching as a time-dependent covariate. Results: In the landmark analysis, the benralizumab group (n=4) had a higher flare rate than the mepolizumab group (n=10) (log-rank test, P = 0.002). However, the Cox model did not converge and the time-dependent analysis yielded an imprecise estimate (hazard ratio 3.14, 95% confidence interval 0.31–32.02). The 1-year flare-free rate after switching to benralizumab (n=19) was 94.1%, and no severe flares occurred. Most patients had low disease activity at switching, and switching was primarily driven by patient preference. Conclusions: Short-term flare-free survival after switching to benralizumab was high despite a small number of minor flares. Further evidence is warranted to assess long-term outcomes.

  • Impact of parenting on patient-reported outcomes in female patients with systemic lupus erythematosus: A cross-sectional study of the LUNA registry

    by Dai Kishida, Takanori Ichikawa, Yasuhiro Shimojima, Nobuyuki Yahima, Ken-Ei Sada, Yoshia Miyawaki, Ryusuke Yoshimi, Shigeru Ohno, Kunihiro Ichinose, Ayuko Takatani, et al.

    Objectives: Although pregnancy and childbirth are critical for patients with systemic lupus erythematosus (SLE), patients who continue to parent their children during treatment have received little attention. In this study, we aimed to investigate the impact of parenting on the quality of life (QoL) of patients with SLE. Methods: This cross-sectional study used data from the Lupus Registry of Nationwide Institutions. The participants were females with SLE. The exposure was parenting, categorized according to the children’s age (including young children [0–5 years] and school-aged children [6–18 years]). The primary outcome was QoL, which was measured using the Lupus Patient-Reported Outcomes (LupusPRO) scale. Multiple regression analysis was performed to assess the association between parenting and QoL adjusted for patient age, number of children, disease activity, disability, living with a spouse, caregiving, and glucocorticoid dosage as confounding factors. Results: Overall, 630 patients (median age, 44 years; median disease duration, 12 years) were included: 71 with young children, 50 with school-aged children only, and 509 without children. None of the LupusPRO scores were significantly lower in patients with children than in patients without children. Patients with young children had significantly better cognitive scores (memory and concentration) than those without children (regression coefficient: 12.16, 95% confidence interval: 0.97–23.35, p = 0.033). Conclusion: Parenting of young children did not worsen QoL in patients with SLE; rather, it was associated with better cognitive function. These findings may help reduce anxiety or hesitation regarding parenting among patients with SLE who wish to become mothers.

  • Open Access

    Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study

    by Hirofumi Miyake, Akira Onishi, Hideaki Tsuji, Takuya Kotani, Yumiko Wada, Yuji Nozaki, Toshihiko Shiga, Shigeru Iwata, Takao Fujii, Yasuhiro Kato, et al.

    Objectives: To identify the factors associated with flares after glucocorticoid (GC) reduction in systemic lupus erythematosus (SLE) and to determine whether belimumab (BLM) influences this risk. Methods: Using the ANSWER-SLE cohort, this retrospective, multicentre study enrolled 388 patients with a GC reduction from ≤5 mg/day. The primary outcome was the time to an overall flare (SLE Disease Activity Index 2000 [SLEDAI-2K] increase of ≥3 or a GC escalation). Multivariable Cox models identified factors associated with an overall flare. Propensity score-based matching weights were applied, and weighted Cox models assessed the association between BLM and flare risk. Results: During a 1-year follow-up, 133 overall flares occurred (1-year cumulative incidence 39.9%). A higher clinical SLEDAI (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.03–1.17), Systemic Lupus International Collaborating Clinics Damage Index (SDI) (HR 1.11, 95% CI 1.01–1.22), and GC dose reduction (HR 1.40, 95% CI 1.15–1.70) were associated with an increased overall flare risk. GC reductions of >1 mg were associated with flare (HR 2.53, 95% CI 1.54–4.15). In the weighted analyses, BLM was not associated with an overall flare (HR 0.83, 95% CI 0.51–1.34). Conclusions: In patients with SLE, carefully tapering GC doses from ≤5 mg/day according to disease activity and organ damage may be important, whereas BLM was not associated with a reduced flare risk.

  • Open Access

    Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis

    by Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, et al.

    Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.


  • Open Access

    Optimal glucocorticoid tapering in anti-synthetase syndrome–associated interstitial lung disease: A multicentre MYKO cohort study

    by Hirofumi Miyake, Takuya Kotani, Takayasu Suzuka, Shogo Matsuda, Katsumasa Oe, Mahiro Yamamoto, Chifumi Akiyama, Takahiro Seno, Takashi Kida, Tomoya Sagawa, et al.

    Objectives: To explore glucocorticoid tapering targets in patients with acute/subacute anti-synthetase syndrome–associated interstitial lung disease (ASyS-ILD). Methods: We retrospectively analysed 86 patients with newly diagnosed acute/subacute ASyS-ILD from the MYKO cohort. Patients were grouped using prednisolone-equivalent dose thresholds of 15, 12.5, and 10 mg/day at 6 months. Exploratory three-group analyses categorised patients into ≤ 12.5, 12.5–15, and >15 mg/day. Matching weights adjusted for baseline confounders. Cox proportional-hazards models evaluated 5-year all-cause mortality and event-free survival for disease flares and infections requiring hospitalisation. A multivariable logistic regression assessed factors associated with achieving ≤ 15 mg/day at 6 months. Results: In two-group analyses, the ≤ 15 mg/day group had a lower infection risk (hazard ratio 0.18, 95% confidence interval 0.04–0.81), whereas analyses using other thresholds showed no clear differences. In the three-group analyses, patients receiving 12.5–15 mg/day tended to have the lowest flare risk. Female sex was associated with achieving ≤ 15 mg/day at 6 months (odds ratio 3.29, 95% confidence interval 1.09–10.13). Conclusions: Tapering to a prednisolone-equivalent dose of 12.5–15 mg/day at 6 months may represent a reasonable target to balance risks of flares and infections in patients with acute/subacute ASyS-ILD.

  • Open Access

    Microscopic Polyangiitis Initially Suspected of Being Anti-synthetase Syndrome

    by Tomoo Tsujihata, Hirofumi Miyake, Eri Iwai-Kanai, Shinji Sumiyoshi, Takeshi Kubo, Ichizo Nishino, Kazuhiro Hatta

    Anti-synthetase syndrome is an autoimmune disorder associated with anti-aminoacyl-tRNA synthetase antibodies, including anti-Jo-1. However, antibody positivity alone is insufficient for the diagnosis because overlapping features with other diseases may lead to a misdiagnosis. We herein report a 69-year-old woman initially suspected of having anti-synthetase syndrome due to anti-Jo-1 antibody positivity and muscle weakness. Additional findings, including mononeuritis multiplex, purpura, crescentic glomerulonephritis, and strongly positive myeloperoxidase-antineutrophil cytoplasmic antibodies, led to a diagnosis of microscopic polyangiitis. Although anti-Jo-1 antibodies are highly specific, false-positive results can occur. This case highlights the need for a comprehensive evaluation beyond antibody testing to avoid diagnostic errors.

  • Top Cited Papers

    Comparison of predictive validity of the Lupus Patient-Reported Outcome and Short-Form-12 for damage accrual in systemic lupus erythematosus

    by Akira Onishi, Hideaki Tsuji, Tsuneo Sasai, Mirei Shirakashi, Ryosuke Hiwa, Shuichiro Nakabo, Shuji Akizuki, Ran Nakashima, Keisuke Nishimura, Ken-Ei Sada, et al.

    Objectives: A core set of patient-reported outcomes (PROs) for systemic lupus erythematosus (SLE) has not been established, and no studies have compared predictive validity of disease-specific and generic quality of life (QOL) instruments. We aimed to compare the predictive validity of the Lupus PRO and Medical Outcomes Study Short-Form-12 (SF-12) for damage accrual in patients with SLE. Methods: The Lupus PRO questionnaire contains both health-related (HR) and non-HR-QOL measures, whereas the SF-12 indices are the physical component summary (PCS), mental component summary (MCS), and role-social component summary (RCS). Damage accrual was evaluated using an increase of one unit in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We examined the association and predictive accuracy of the Lupus PRO and SF-12 scores at baseline for damage accrual using survival models for recurrent events. Results: Among 1326 patients, those with a higher HR-QOL on Lupus PRO at baseline showed significantly lower damage accrual (hazard ratio: 0.94, 95% confidence interval [CI]: 0.89–0.99), whereas higher PCS and RCS of SF-12 were associated with lower damage accrual (0.92, 95% CI: 0.86–0.98; 0.92, 95% CI: 0.86–0.99). The Akaike Information Criterion, Bayesian Information Criterion, C-index, and area under the curve were comparable between the Lupus PRO and SF-12. Only higher PCS of the SF-12 was associated with glucocorticoid-independent SDI. Conclusion: Predictive metrics and discriminatory performance were comparable between the Lupus PRO and SF-12. Our findings highlight both disease-specific and generic QOL measurements can be valuable options for core set outcomes.